Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283454900> ?p ?o ?g. }
- W4283454900 endingPage "22" @default.
- W4283454900 startingPage "11" @default.
- W4283454900 abstract "BackgroundSystemic treatment patterns and related mental health disorders and economic burden among patients with psoriasis are largely unknown.ObjectiveTo assess systemic treatment patterns and associated depression and anxiety-related health care costs among patients with psoriasis initiating a conventional systemic treatment (CST).MethodsUsing a retrospective cohort design with sequence and cluster analyses, we assessed systemic treatment trajectories (CST and tumor necrosis factor inhibitors or ustekinumab, [TNFi/UST]) over a 2-year period following CST initiation. We compared health care costs between trajectories using 2-part models.ResultsWe included 781 patients and identified 8 trajectories: persistent methotrexate users, persistent acitretin users, early CST discontinuation, late methotrexate discontinuation, switch to TNFi/UST, adding TNFi/UST, discontinuation then restart on methotrexate, and discontinuation then restart on acitretin or multiple CST switches. Overall, 165 (21%) patients incurred depression- and anxiety-related health care costs (median annual cost, CAN$56; quartiles, $14-$127). Compared with persistent methotrexate users, adding a TNFi/UST (cost ratio, 3.63; 95% CI, 1.47-5.97) and discontinuation then restart on acitretin or multiple switches between systemic agents (cost ratio, 13.3; 95% CI 5.76-22.47) had higher costs.LimitationsTrajectory misclassification may have occured. These date represent an association, and causality cannot be inferred, particularly given the risk of confounding.ConclusionDepression- and anxiety-related health care costs were high among patients adding TNFi/UST and those discontinuing then restarting on acitretin or experiencing multiple switches between systemic agents. Systemic treatment patterns and related mental health disorders and economic burden among patients with psoriasis are largely unknown. To assess systemic treatment patterns and associated depression and anxiety-related health care costs among patients with psoriasis initiating a conventional systemic treatment (CST). Using a retrospective cohort design with sequence and cluster analyses, we assessed systemic treatment trajectories (CST and tumor necrosis factor inhibitors or ustekinumab, [TNFi/UST]) over a 2-year period following CST initiation. We compared health care costs between trajectories using 2-part models. We included 781 patients and identified 8 trajectories: persistent methotrexate users, persistent acitretin users, early CST discontinuation, late methotrexate discontinuation, switch to TNFi/UST, adding TNFi/UST, discontinuation then restart on methotrexate, and discontinuation then restart on acitretin or multiple CST switches. Overall, 165 (21%) patients incurred depression- and anxiety-related health care costs (median annual cost, CAN$56; quartiles, $14-$127). Compared with persistent methotrexate users, adding a TNFi/UST (cost ratio, 3.63; 95% CI, 1.47-5.97) and discontinuation then restart on acitretin or multiple switches between systemic agents (cost ratio, 13.3; 95% CI 5.76-22.47) had higher costs. Trajectory misclassification may have occured. These date represent an association, and causality cannot be inferred, particularly given the risk of confounding. Depression- and anxiety-related health care costs were high among patients adding TNFi/UST and those discontinuing then restarting on acitretin or experiencing multiple switches between systemic agents." @default.
- W4283454900 created "2022-06-26" @default.
- W4283454900 creator A5008018875 @default.
- W4283454900 creator A5028992865 @default.
- W4283454900 creator A5065724432 @default.
- W4283454900 creator A5066639630 @default.
- W4283454900 creator A5069697993 @default.
- W4283454900 creator A5073052450 @default.
- W4283454900 creator A5085732815 @default.
- W4283454900 date "2022-12-01" @default.
- W4283454900 modified "2023-10-11" @default.
- W4283454900 title "Trajectories of systemic agent use and associated depression- and anxiety-related health care costs among patients with psoriasis" @default.
- W4283454900 cites W1809686743 @default.
- W4283454900 cites W1877047792 @default.
- W4283454900 cites W1914556171 @default.
- W4283454900 cites W1928823211 @default.
- W4283454900 cites W1948664808 @default.
- W4283454900 cites W1966302952 @default.
- W4283454900 cites W1984920393 @default.
- W4283454900 cites W1987574038 @default.
- W4283454900 cites W1994127723 @default.
- W4283454900 cites W2003982930 @default.
- W4283454900 cites W2012736637 @default.
- W4283454900 cites W2036601710 @default.
- W4283454900 cites W2066752983 @default.
- W4283454900 cites W2070835847 @default.
- W4283454900 cites W2081016717 @default.
- W4283454900 cites W2082347947 @default.
- W4283454900 cites W2084079665 @default.
- W4283454900 cites W2091442391 @default.
- W4283454900 cites W2103120331 @default.
- W4283454900 cites W2114741326 @default.
- W4283454900 cites W2116526448 @default.
- W4283454900 cites W2123277906 @default.
- W4283454900 cites W2155441883 @default.
- W4283454900 cites W2164533070 @default.
- W4283454900 cites W2168911501 @default.
- W4283454900 cites W2299183348 @default.
- W4283454900 cites W2346598705 @default.
- W4283454900 cites W2464005302 @default.
- W4283454900 cites W2550960301 @default.
- W4283454900 cites W2595081199 @default.
- W4283454900 cites W2599076725 @default.
- W4283454900 cites W2612649733 @default.
- W4283454900 cites W2613397542 @default.
- W4283454900 cites W2737441677 @default.
- W4283454900 cites W2743993411 @default.
- W4283454900 cites W2746562707 @default.
- W4283454900 cites W2766452106 @default.
- W4283454900 cites W2811216347 @default.
- W4283454900 cites W2889154468 @default.
- W4283454900 cites W2899624130 @default.
- W4283454900 cites W2901528591 @default.
- W4283454900 cites W2909384207 @default.
- W4283454900 cites W2910974211 @default.
- W4283454900 cites W2914164523 @default.
- W4283454900 cites W2943076972 @default.
- W4283454900 cites W2955984147 @default.
- W4283454900 cites W2976277449 @default.
- W4283454900 cites W2996373353 @default.
- W4283454900 cites W3007389533 @default.
- W4283454900 cites W3008855491 @default.
- W4283454900 cites W3103720204 @default.
- W4283454900 cites W3106805995 @default.
- W4283454900 cites W3123140680 @default.
- W4283454900 cites W3134034280 @default.
- W4283454900 cites W3173226927 @default.
- W4283454900 cites W4248429808 @default.
- W4283454900 cites W65111514 @default.
- W4283454900 doi "https://doi.org/10.1016/j.jdin.2022.06.018" @default.
- W4283454900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35996750" @default.
- W4283454900 hasPublicationYear "2022" @default.
- W4283454900 type Work @default.
- W4283454900 citedByCount "1" @default.
- W4283454900 countsByYear W42834549002023 @default.
- W4283454900 crossrefType "journal-article" @default.
- W4283454900 hasAuthorship W4283454900A5008018875 @default.
- W4283454900 hasAuthorship W4283454900A5028992865 @default.
- W4283454900 hasAuthorship W4283454900A5065724432 @default.
- W4283454900 hasAuthorship W4283454900A5066639630 @default.
- W4283454900 hasAuthorship W4283454900A5069697993 @default.
- W4283454900 hasAuthorship W4283454900A5073052450 @default.
- W4283454900 hasAuthorship W4283454900A5085732815 @default.
- W4283454900 hasBestOaLocation W42834549002 @default.
- W4283454900 hasConcept C118552586 @default.
- W4283454900 hasConcept C126322002 @default.
- W4283454900 hasConcept C139719470 @default.
- W4283454900 hasConcept C16005928 @default.
- W4283454900 hasConcept C162324750 @default.
- W4283454900 hasConcept C187212893 @default.
- W4283454900 hasConcept C2776867660 @default.
- W4283454900 hasConcept C2777575956 @default.
- W4283454900 hasConcept C2778496887 @default.
- W4283454900 hasConcept C2778715236 @default.
- W4283454900 hasConcept C2778975655 @default.
- W4283454900 hasConcept C2780132546 @default.
- W4283454900 hasConcept C2780564577 @default.
- W4283454900 hasConcept C2781059491 @default.